NRT + QuitBuddy-Recall for Relapse

Phase-Based Progress Estimates
Relapse+1 More
NRT + QuitBuddy-Recall - Other
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a smartphone app can help people quit smoking.

Eligible Conditions
  • Relapse
  • Smoking, Cessation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Relapse

Study Objectives

0 Primary · 1 Secondary · Reporting Duration: 1 week

1 week
Abstinence from cigarettes

Trial Safety

Safety Progress

1 of 3

Other trials for Relapse

Trial Design

3 Treatment Groups

NRT Control (treatment as usual)
1 of 3
NRT + QuitBuddy-Recall
1 of 3
NRT + QuitBuddy
1 of 3
Active Control
Experimental Treatment

94 Total Participants · 3 Treatment Groups

Primary Treatment: NRT + QuitBuddy-Recall · No Placebo Group · N/A

NRT + QuitBuddy-Recall
Experimental Group · 1 Intervention: NRT + QuitBuddy-Recall · Intervention Types: Other
NRT + QuitBuddy
Experimental Group · 1 Intervention: NRT + QuitBuddy · Intervention Types: Other
NRT Control (treatment as usual)
ActiveComparator Group · 1 Intervention: Treatment as Usual · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,225 Previous Clinical Trials
5,612,833 Total Patients Enrolled
Medical University of South CarolinaOTHER
832 Previous Clinical Trials
5,371,930 Total Patients Enrolled
Meharry Medical CollegeLead Sponsor
16 Previous Clinical Trials
5,410 Total Patients Enrolled
Bryan W Heckman, PhDPrincipal InvestigatorMeharry Medical College

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.